SCHEMBL541316

SCHEMBL541316

C=CCOC(=O)C(C#N)=CCC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTP4A1 Q93096 3/20 0.46
PTP4A3 O75365 2/20 0.46
PTP4A2 Q12974 1/20 0.45
CYP2C9 P11712 1/20 0.44
MAPT P10636 4/20 0.40
NPC1 O15118 4/20 0.40
RAB9A P51151 4/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
NPSR1 Q6W5P4 3/20 0.40
KDM4E B2RXH2 2/20 0.40
USP2 O75604 2/20 0.40
GAA P10253 2/20 0.40
HTT P42858 2/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
THRB P10828 1/20 0.40
HPGD P15428 1/20 0.40
MCOLN3 Q8TDD5 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7482640 0.82 PTP4A1 (0.43) PTP4A1PTP4A3PTP4A2CYP2C9MAPT
SCHEMBL7482643 0.82 PTP4A1 (0.43) PTP4A1PTP4A3PTP4A2CYP2C9MAPT
SCHEMBL11269373 0.82 CYP2C9 (0.62) PTP4A1CYP2C9MAPTNPC1RAB9A
SCHEMBL167038 0.82 CYP2C9 (0.62) PTP4A1CYP2C9MAPTNPC1RAB9A
SCHEMBL6293723 0.80 PTP4A1 (0.49) PTP4A1PTP4A3PTP4A2CYP2C9MAPT
SCHEMBL1566520 0.80 CYP2C9 (0.45) PTP4A1PTP4A3PTP4A2CYP2C9MAPT
SCHEMBL1566521 0.80 CYP2C9 (0.45) PTP4A1PTP4A3PTP4A2CYP2C9MAPT
SCHEMBL4088999 0.80 CYP2C9 (0.45) PTP4A1PTP4A3PTP4A2CYP2C9MAPT
SCHEMBL7117459 0.79 PTP4A3 (0.48) PTP4A1PTP4A3PTP4A2CYP2C9MAPT
SCHEMBL7117452 0.79 PTP4A3 (0.48) PTP4A1PTP4A3PTP4A2CYP2C9MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2089308-B1 DISPENSER ETHICON INC (US) 2018-12-26 EP disclosed
CN-105980511-A Screen frame configuration and screen device 日立化成株式会社 2016-09-28 CN disclosed
US-8287202-B2 Method for dispensing a polymerizable monomer adhesive ETHICON, INC. (US) 2012-10-16 US disclosed
US-20120160867-A1 DISPENSER WITH A FRANGIBLE CONTAINER AND A ROTATING BREAKING MEMBER, FOR DISPENSING A POLYMERIZABLE MONOMER ADHESIVE CLOSURE MEDICAL CORPORATION 2012-06-28 US disclosed
US-8118508-B2 Dispenser with a frangible container and a rotating breaking member, for dispensing a polymerizable monomer adhesive CLOSURE MEDICAL CORPORATION (US) 2012-02-21 US disclosed
EP-2413943-A1 CONTROLLED EXOTHERM OF CYANOACRYLATE FORMULATIONS Ethicon, Inc (US) 2012-02-08 EP disclosed
US-7932305-B2 Viscous α-cyanoacrylate compositions ETHICON, INC. (US) 2011-04-26 US disclosed
US-20100269749-A1 Absorbable Cyanoacrylate Compositions ETHICON, INC. 2010-10-28 US disclosed
WO-2010114779-A1 CONTROLLED EXOTHERM OF CYANOACRYLATE FORMULATIONS ETHICON, INC. (US) 2010-10-07 WO disclosed
US-20100249698-A1 CONTROLLED EXOTHERM OF CYANOACRYLATE FORMULATIONS ETHICON, INC. 2010-09-30 US disclosed
WO-2009158302-A2 VISCOUS ALPHA-CYANOACRYLATE COMPOSITIONS CLOSURE MEDICAL CORPORATION (US) 2009-12-30 WO disclosed
EP-2089308-A2 DISPENSER Closure Medical Corporation (US) 2009-08-19 EP disclosed
US-20080241249-A1 Cyanoacrylate composite CLOSURE MEDICAL CORPORATION (US) 2008-10-02 US disclosed
EP-1928920-A2 IMPROVED STABILIZER CYANOACRYLATE FORMULATIONS Closure Medical Corporation (US) 2008-06-11 EP disclosed
WO-2008067220-A2 DISPENSER CLOSURE MEDICAL CORPORATION (US) 2008-06-05 WO disclosed
US-20080131190-A1 Dispenser ETHICON, INC. 2008-06-05 US disclosed
WO-2008005634-A1 ABSORBABLE CYANOACRYLATE COMPOSITIONS CLOSURE MEDICAL CORPORATION (US) 2008-01-10 WO disclosed
US-20080003196-A1 Absorbable cyanoacrylate compositions ETHICON, INC. 2008-01-03 US disclosed
WO-2007041143-A2 IMPROVED STABILIZER CYANOACRYLATE FORMULATIONS CLOSURE MEDICAL CORPORATION (US) 2007-04-12 WO disclosed
US-20070078207-A1 Stabilizer cyanoacrylate formulations ETHICON, INC. 2007-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080241249-A1 Cyanoacrylate composite ALOX5, SCD, SCD5 PTP4A1 2061/4885PTP4A3 2475/4885PTP4A2 3161/4885
US-20080003196-A1 Absorbable cyanoacrylate compositions PCNA, FGB, F13A1 PTP4A1 4621/4885PTP4A3 4752/4885PTP4A2 4774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.